Tirzepatide does not reduce all-cause mortality in patients with type 2 diabetes and asthma compared to other GLP-1 receptor agonists
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.